Pegylated interferon α2b versus pegylated interferon α2a for chronic hepatitis C: The unreached goal of superiority

Journal of Hepatology

Volumn 51, Issue 6, 2009, Pages 1097-1099

  Rumi, Maria Grazia ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SAFETY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 71549141619     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.09.013     Document Type: Article

References (12)

1. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
2. Fried M.W., Shiffman M., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirn for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Di Bisceglie A.M., Ghalib R.H., Hamzeh F.M., and Rustgi V.K. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hep 14 (2007) 721729
4. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361 (2009) 580-593
5. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J.C., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34 (2001) 395-403
6. Reddy K.R., Shiffman M.L., Morgan T.R., Zeuzem S., Hadziyannis S., Hamzeh F.M., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 5 (2007) 124-129
7. Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 46 (2007) 1688-1694
8. Kanwal F., Hoang T., Spiegel B.M., et al. Predictors of treatment in patients with chronic hepatitis C infection: role of patients versus nonpatient factors. Hepatology 46 (2007) 1741-1749
9. Backus L.I., Boothroyd D.B., Phillips B.R., Mole L.A., Elsen S., Dominitz J.A., et al. Predictors of response of US veterans to treatment for hepatitis C virus. Hepatology 46 (2007) 37-47
10. Witthoeft T., Hueppe D., John C., Golz J., Meyer U., Heyne R., et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the PRACTICE Study. J Hepatol 48 (2008) S315
11. Ascione A., De Luca M., Tartaglione M.T., Lampasi F., Galeota Lanza A., Picciotto F.P., et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J Hepatol 48 (2008) S370
12. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of PEG-interferon-α2a plus ribavirin versus PEG-interferon-α2b plus ribavirin in chronic hepatitis C. Gastroenterology, in press. doi:10.1053/j.gastro.2009.08.071.